The challenges of treating moderate to severe psoriasis

International Journal of Dermatology

Volumn 36, Issue SUPPL. 1, 1997, Pages 41-44

  Gottlieb, Alice Bendix ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; ETRETINATE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE;

CONFERENCE PAPER; DISEASE SEVERITY; DRUG INDUCED DISEASE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LIVER TOXICITY; NEPHROTOXICITY; PHOTOTHERAPY; PSORIASIS; PUVA; SKIN DISEASE; T LYMPHOCYTE ACTIVATION; TERATOGENICITY; TREATMENT OUTCOME;

EID: 0031473870     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-4362.36.s1.4.x     Document Type: Conference Paper

References (12)

1. National Psoriasis Foundation. Patients hail education, support in psoriasis therapy. Dermatology Perspectives 1986; 2: 6.
2. Krueger JG, Wolfe JT, Nabeya RT, et al. Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells. J Exp Med 1995; 182: 2057-2068.
3. 389 IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nature Medicine 1995; 1: 442-447.
4. Vallat VP, Gilleaudeau L, Battat J, et al. PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy. J Exp Med 1994; 180: 283-296.
5. Lu I, Gilleaudeau P, McLane JA, et al. Modulation of epidermal differentiation, tissue inflammation, and T-lymphocyte infiltration in psoriatic plaques by topical calcitriol. J Cutan Pathol 1996; 23: 419-430.
6. Gottlieb AB, Grossman RM, Khandke L, et al. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol 1992; 98: 302-309.
7. Gottlieb S, Hayes E, Gilleaudeau P, et al. Cellular actions of etretinate in psoriasis: enhanced epidermal differentiation and reduced cell-mediated inflammation are unexpected outcomes. J Cutan Pathol 1996; 23: 404-418.
8. Gerritsen MJ, Boezeman JB, Van Vlijmen-Willems JJ, et al. The effect of tacalcitol (1,24 (OH) 2D3) on cutaneous inflammation, epidermal proliferation and keratinization in psoriasis: a placebo-controlled, double-blind study. Br J Dermatol 1994; 131: 57-63.
9. Baker BS, Griffiths CE, Lambert S, et al. The effects of cyclosporine A on T lymphocyte and dendritic cell sub-populations in psoriasis. Br J Dermatol 1987; 116: 503-510.
10. Gottlieb AB. Product development in psoriasis: Clinical challenges and opportunities. In: Roenigk H, Maibach H, eds. Psoriasis, 3rd edn, New York, NY: Marcel Dekker, in press.
11. Stern RS, Nichols KT, Vakeva LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). N Engl J Med 1997; 336: 1041-1045.
12. β13. 1 genes. Proc Natl Acad Sci USA 1994; 91: 9282-9286.